Registered Office: - Plot No. 440/4, 5 & 6, Road No. 82/A, G.I.D.C. Sachin, Surat - 394230, Dist. Surat, Gujarat, India.

# December 14, 2023

To. The Listing Department, BSE LIMITED, Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai- 400 001

**Scrip Code: 543349** 

Τo, The Listing Department National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No. C-1, G-Block, Bandra Kurla Complex, Mumbai -400051

**NSE Symbol: AMIORG** 

Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release titled Ami Organics and Fermion ink another agreement for two additional Advanced Pharmaceutical Intermediate with Fermion dated December 14, 2023 for dissemination.

This Press Release will be available on the website of the Company www.amiorganics.com.

Kindly take the same on record.

Yours faithfully, For, AMI ORGANICS LIMITED

Ekta Kumari Srivastava Company Secretary & Compliance Officer

Encl: Press Release







# Ami Organics and Fermion ink another agreement for two additional Advanced Pharmaceutical Intermediate with Fermion

**Surat, December 14, 2023:** Ami Organics Limited (BSE: 543349, NSE: AMIORG) a leading global manufacturer of advanced pharmaceutical intermediates and speciality chemicals, has signed another definitive agreement with Fermion, a fully owned subsidiary of Orion Corporation, Finland. As part of the agreement, Ami Organics will manufacture couple of additional advanced pharmaceutical intermediates for Fermion.

The two additional advanced pharmaceutical intermediates signed today will be used in captive consumption for the manufacture of earlier advanced pharmaceutical intermediates signed with Fermion. This agreement will lead to value addition to the final advanced intermediates which will be supplied by Ami Organics to Fermion, leading to higher value of end product. This will also help company become leading supplier of Fermion, supplying key advanced intermediates.

The products are slated to be manufactured at the Ankleshwar Facility and is expected to start contributing meaningfully to the revenue from FY25.

Ami Organics has already signed two agreements with Fermion in November 2022 and September 2023 for supply of two advanced pharmaceutical intermediates. This agreement is in addition to the previous agreements and further increases the total value of the CDMO contract with Fermion.

Commenting on development, Mr. Naresh Patel, Executive Chairman & Managing Director, Ami Organics Limited, said: "I am happy to inform you that we continue to strengthen our relationship with our esteem customer — Fermion, with signing of two more advanced pharmaceutical intermediates. The new agreement marks a significant stride forward in our collaboration with Fermion showcasing our dedication for delivering more value-added products to our customers and the trust reposed on our capabilities."

## **ABOUT AMI ORGANICS LIMITED:**

Ami Organics, headquartered at Surat, is a R&D driven manufacturer of specialty chemicals with varied end usage, focussed on the development and manufacturing of advanced pharmaceutical intermediates ("Pharma Intermediates") for regulated markets and generic active pharmaceutical ingredients ("APIs") and New Chemical Entities ("NCE") and key starting material for agrochemical and fine chemicals. Ami Organics has developed and commercialised over 520+ Pharma Intermediates for APIs across 23 key therapeutic areas since inception and NCE, with a strong focus on R&D across select high-growth high margin chronic therapeutic areas.

### **ABOUT FERMION:**

#### **PRESS RELEASE**

For Immediate dissemination



Fermion is a Finnish manufacturer of active pharmaceutical ingredients (APIs) and part of Orion Group. Fermion develops and manufactures APIs for Orion. Fermion also develops, manufactures and markets APIs to companies in global generic market as well as under exclusive contracts to companies focusing on new chemical entities (NCEs).

# **CAUTIONARY STATEMENT:**

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Ami Organics has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

#### For details, please contact:

Investor Relations at Ami Organics	Registered Office
------------------------------------	-------------------

Ekta Srivastava, Company Secretary & Plot no. 440/4, 5 & 6, Road No. 82/A,

Compliance Officer GIDC Sachin, Surat- 394230 <u>cs@amiorganics.com</u> CIN: L24100GJ2007PLC051093

Ernst & Young ISIN: INE00FF01017
NSE Code: AMIORG
Mr. Rahul Thakur BSE CODE: 543349

Rahul.thakur@in.ey.com Website: www.amiorganics.com